SELLAS Life Sciences Group, Inc. short interest in 2020
In 2020, SELLAS Life Sciences Group, Inc.'s disclosed short interest ran from 5.41% of shares outstanding on 13 Mar 2020 to 7.95% on 31 Dec 2020, a change of +2.54 percentage points. The year's high was 13.31% on 15 Dec 2020 and its low 1.40% on 14 Aug 2020, averaging 4.26% across 20 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 8.83 days on 30 Oct 2020. Full history: SELLAS Life Sciences Group, Inc..
Cite this page
By year: 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2020 in figures
- Start of year
- 5.41% (13 Mar 2020)
- End of year
- 7.95% (31 Dec 2020)
- Change
- +2.54 pp
- High
- 13.31% (15 Dec 2020)
- Low
- 1.40% (14 Aug 2020)
- Average
- 4.26%
- Highest days to cover
- 8.83 (30 Oct 2020)
- SEC filings marked
- 8
Every report in 2020
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 13 Mar 2020 | 5.41% | 1.40 | 10-K filed, results (8-K) |
| 31 Mar 2020 | 4.32% | 1.96 | |
| 15 Apr 2020 | 3.41% | 1.85 | |
| 30 Apr 2020 | 3.26% | 1.13 | |
| 15 May 2020 | 3.91% | 1.43 | 10-Q filed, results (8-K) |
| 29 May 2020 | 3.40% | 1.00 | |
| 15 Jun 2020 | 2.81% | 1.00 | |
| 30 Jun 2020 | 2.48% | 1.37 | |
| 15 Jul 2020 | 3.09% | 1.32 | |
| 31 Jul 2020 | 2.94% | 2.28 | |
| 14 Aug 2020 | 1.40% | 1.17 | 10-Q filed, results (8-K) |
| 31 Aug 2020 | 1.57% | 1.00 | |
| 15 Sep 2020 | 3.15% | 1.37 | |
| 30 Sep 2020 | 4.43% | 2.38 | |
| 15 Oct 2020 | 4.36% | 5.82 | |
| 30 Oct 2020 | 4.36% | 8.83 | |
| 13 Nov 2020 | 3.87% | 7.07 | 10-Q filed, results (8-K) |
| 30 Nov 2020 | 5.85% | 1.81 | |
| 15 Dec 2020 | 13.31% | 1.00 | |
| 31 Dec 2020 | 7.95% | 1.00 |
See also: SELLAS Life Sciences Group, Inc.'s full history · most shorted US stocks of 2020 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.